
How can the KISQALI dose be adjusted to help manage adverse reactions?
For patients with stage II/III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (eBC) at high risk of recurrence, in combination with an aromatase inhibitor (AI), the once-daily KISQALI® (ribociclib) dose can be reduced from 400 mg (2 x 200-mg tablets) orally to one 200-mg tablet, as needed, to help manage adverse reactions. See clinical guidance below for KISQALI dose adjustments in eBC.1
DOSE REDUCTIONS
For patients with stage II/III HR+/HER2- eBC,
Dose reductions with KISQALI mean no need for new mid-cycle prescriptions or additional costs
KISQALI is given as 400 mg (two 200-mg tablets) orally, once daily (3 weeks on, 1 week off) for 3 years with an AI1
Review the full Prescribing Information for recommended dosing of selected AI
An LHRH agonist should be used concomitantly with AI in men and premenopausal women
Dose adjustments for adverse reactions should be made by reducing the number of tablets taken to 1 x 200-mg tablet1
If dose reduction below 200 mg/day is required, discontinue treatment
KISQALI dose modification is recommended based on individual safety and tolerability
KISQALI can be taken with or without food
AI, aromatase inhibitor; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; LHRH, luteinizing hormone-releasing hormone.

